Status:
COMPLETED
Treatment of Peri-Implant Mucositis With Standard of Care and Bioptron Hyperlight Therapy
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Mucositis Oral
Dental Implant Failed
Eligibility:
All Genders
Phase:
NA
Brief Summary
Objectives: The aim of this study was to evaluate in a cohort of patients with peri-implant mucositis: (a) the efficacy of professional mechanical debridement therapy assisted using Bioptron Hyperlig...
Eligibility Criteria
Inclusion
- Male or female, 30-60 years old.
- With diagnosis of peri-implant mucositis.
- Plaque index (PI) ≥ 40%.
- Al least one implant site with PPD≥4 mm, BOP+ and suppuration.
- No uncontrolled diabetes, cardiovascular diseases, bone metabolism disorders, no autoimmune diseases (lichen planus, pemphigoid, pemphigus and systemic lupus erythematosus).
- No pharmacological therapies, no chemo-radiotherapies.
- No smoking (\>10 cigarettes/day), alcohol and/or drug consumption.
- No pregnancy or breastfeeding.
- No allergy.
Exclusion
- \-
Key Trial Info
Start Date :
January 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05307445
Start Date
January 7 2020
End Date
January 13 2022
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roberto Felice Grassi
Bari, Italy, 70121